IP Library › Granted Patent US 7,034,126
Granted Patent B2
US 7,034,126 · App. 10/844,865 · Granted Apr 25, 2006

Lactoferrin in the treatment of diabetes mellitus

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,034,126
App. No.
10/844,865
Granted
Apr 25, 2006
Kind
B2
Abstract

The present invention relates to methods of using a composition of lactoferrin for the treatment of diabetes mellitus as manifested by a reduction in the levels of serum glucose, blood pressure, obesity, or glycosylated hemoglobin (HbAlc).

Claims (24)

1. A method of treating diabetes mellitus comprising administering to a subject an effective amount of a composition having an N-terminal lactoferrin variant, wherein the amount of said lactoferrin composition decreases blood levels of glucose and insulin thereby treating diabetes mellitus, and wherein the N-terminal lactoferrin variant retains the biological activity of full length lactoferrin.

2. The method of claim 1 , wherein said N-terminal lactoferrin variant is mammalian lactoferrin.

3. The method of claim 1 , wherein said N-terminal lactoferrin variant is human or bovine lactoferrin.

4. The method of claim 1 , wherein said N-terminal lactoferrin variant is recombinant lactoferrin.

5. The method of claim 1 , wherein the N-terminal lactoferrin variant lacks at least the N-terminal glycine residue.

6. The method of claim 1 , wherein said N-terminal lactoferrin variant comprises at least 1% to at least 50% w/w of the lactoferrin composition.

7. The method of claim 1 , wherein said diabetes mellitus is non-insulin dependent diabetes mellitus.

8. The method of claim 1 , wherein the blood pressure in said subject is reduced.

9. The method of claim 1 , wherein total body weight of the subject is reduced.

10. The method of claim 1 , wherein said blood glucose is monitored by the level of glycosylated hemoglobin (HbA1c).

11. The method of claim 1 , wherein said composition is dispersed in a pharmaceutically acceptable carrier.

12. The method of claim 1 , wherein said composition is administered orally.

13. The method of claim 12 , wherein the composition is administered in a delayed release formulation.

14. The method of claim 13 , wherein the N-terminal lactoferrin variant release occurs in the small intestine.

15. The method of claim 13 , wherein the N-terminal lactoferrin variant release release occurs in the large intestine.

16. The method of claim 1 , wherein said composition is administered parenterally.

17. The method of claim 16 , wherein parenteral administration is intravenously or intramuscularly.

18. The method of claim 1 , wherein said composition is administered topically.

19. The method of claim 18 , wherein topical administration is subcutaneously or dermally.

20. The method of claim 1 , wherein the amount of the composition that is administered is about 1 μg to about 20 g per day.

21. The meted of claim 1 , wherein the amount of the composition that is administered is about 0.1 g to about 5 g per day.

22. A method of treating hyperglycemia in a subject comprising administering to a subject an effective amount of a composition having an N-terminal lactoferrin variant, wherein the amount of said lactoferrin composition decreases blood glucose, and wherein the N-terminal lactoferrin variant retains the biological activity of full length lactoferrin.

23. The method of claim 22 , wherein said blood glucose is monitored by the level of glycosylated hemoglobin (HbA1c).

24. The method of claim 22 , wherein the subject suffers from diabetes mellitus.